Genetic testing startup 23andMe, which filed for bankruptcy earlier this year, announced on Monday that it has agreed to sell the genetic data of its 15 million users, along with its core business, to drug developer Regeneron Pharmaceuticals. The acquisition, which followed a bankruptcy auction, is valued at $256 million and is expected to close in the third quarter of this year.
Regeneron told 23andMe customers that it would adhere to 23andMe’s privacy policy, which allows customers to request to delete their personal information.
Related: ‘Surprised and Disappointed’: All Independent Board Members of 23andMe Resign, Leaving Only the CEO
“We assure 23andMe customers that we are committed to protecting the 23andMe